Sun Pharma's Ranbaxy buy is good for pharma

Sun Pharma's acquisition of stressed generics drugmaker Ranbaxy Laboratories in a $4-billion deal including debt is welcome. The all-stock deal is good for investors, boosts pharma stocks in general and gives a leg up to consolidation in the pharmaceutical space that is primed for growth in the US and emerging markets.

Read Full Story>>